Please assess the completion status of the following clinical trial:

Trial Title: APERTO CVS PMCF Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients age \>18, no pregnant women, able to perform fup visits, life expectancy \> 12 months~* Dialysis patients undergoing endovascular angioplasty due to clinically symptomatic stenosis (de novo or restenosis) of the central veins with significant (\>50%) stenosis and diameter~* The target lesion consists of one or more lesions with a target lesion length of less than or equal to 100 mm~* The target blood vessel diameter of the target lesion is between 6.0 and 16.0 mm (in angiographic or ultrasound evaluation);~* If there are other non-target lesions, then non-target lesions must be successfully cured with a not drug coated balloon before treating the target lesion;~Exclusion Criteria:~* Patients with CVS observed and estimated as nonsignificant (\< 50% stenosis) or a vessel \> 12 mm in diameter by visual estimation;~* the patient is now participating in another clinical trial to evaluate drug or medical device;~* patient enrolled for this trial before;~* prenatal pregnancy test result for women of childbearing potential is non-negative, Lactating woman;~* patients, who underwent major surgical procedures (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study;~* patients scheduled to undergo major surgery (eg, thoracotomy, craniotomy, etc.) within 30 days after enrolment;~* central veins lesions have been already treated with DCB before~* presence of a bare metal stent (BMS) or stent graft or vascular access thrombosis in central veins~* patients allergic or intolerant to paclitaxel, or contrast media;~* patients whose life expectancy is less than 1 year~* presence of Thrombus in central veins~* tumor compression~* thoracic inlet syndrome~* patients implanted with pacing or cardioverter devices with leads~* any other central line within the target lesion~* Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APERTO OTW DCB (Type: None): Dialysis patients treated with APERTO OTW following (re)stenosis of central veins

Based on this trial design, predict the completion outcome and termination type (if applicable).